What Monarch Medical Technologies does

Monarch Medical Technologies develops and markets the EndoTool Glucose Management System, an FDA-cleared Class II medical device that delivers patient-specific insulin dosing recommendations for inpatient glycemic management. Founded in 2003 by Dr. Patrick Burgess, the company built its core technology around a proprietary adaptive algorithm that incorporates 11+ patient-specific clinical factors—including renal function, weight, age, sex, and real-time glucose values—and continuously recalculates dosing recommendations. A distinctive feature is the Estimated Residual Extracellular Insulin (EREI) calculation, which models residual circulating insulin to prevent overdosing, particularly in patients with renal impairment. The product portfolio comprises EndoTool IV for intravenous insulin therapy, EndoTool SubQ for subcutaneous insulin delivery, and the newly-cleared EndoTool IV Cloud, a cloud-based architecture launched in 2026.

The company generates revenue through direct enterprise sales to U.S. hospital systems under multi-year subscription contracts, with pricing scaled to organization size and modules. The go-to-motion is enterprise field sales targeting hospital leadership, pharmacy, quality/safety, and clinical decision-makers, supported by 15-minute product demonstrations, on-site and remote training, EHR integration services, and ongoing customer success management. Customers include Trinity Health, Corewell Health, Atrium Health Wake Forest Baptist, UPMC, Sharp HealthCare, Beacon Health System, Northside Hospital, CaroMont Health, Cone Health, and Temple Health, with the platform deployed across 100+ U.S. health systems including 8 of the top 10. The product maintains deep HL7-based integrations with Epic, Cerner/Oracle Health, and Meditech, and is supported by over 50 peer-reviewed clinical studies documenting outcomes such as severe hypoglycemia rates as low as 0.005%, $12M in savings for a single health system, and 84% decreases in hypoglycemic events.

In September 2025, Monarch was acquired by Glooko, a California-based digital health company that had raised a $100M Series F in October 2024, integrating EndoTool into a comprehensive hospital-to-home diabetes management platform. The company now operates as "Monarch Medical Technologies, a Glooko Company" and holds SOC 2 Type II, ISO 13485, and FDA 21 CFR Part 11 compliance certifications. Headquartered in Charlotte, North Carolina with 11-50 employees, Monarch continues to sell and support EndoTool alongside Glooko's outpatient diabetes management portfolio, with the May 2026 EndoTool IV Cloud FDA 510(k) clearance marking the most recent expansion of the product platform.

Name

Monarch Medical Technologies

Legal name

Monarch Medical Technologies LLC

Website

https://monarchmedtech.com

Company type

Private

Founded year

2003

Operating status

Acquired

Headcount range

11–50 employees

Short description

Monarch Medical Technologies provides EndoTool, an FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, serving 100+ U.S. hospital systems with adaptive algorithms and EREI calculations. Acquired by Glooko in September 2025 to form an integrated hospital-to-home diabetes platform.

Ownership category

akta.pro rank

Product category

Clinical Decision Support Software

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industry

Diabetes (General) (HLAKADAA)

Keywords

• Insulin dosing software
• Glycemic management system
• Inpatient diabetes management
• Clinical decision support
• Patient-specific dosing

Headquarters

HQ city

Charlotte

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Software Subscription / License: Enterprise software licensing model for hospital systems. Pricing varies based on hospital size, number of locations, and specific product modules (EndoTool IV and/or SubQ). Includes implementation, training, and ongoing support as part of the contract.
2. Professional Services (Implementation & Training): Implementation services include pre-launch preparation, discovery and scoping, technical build-out, EHR integration testing, and clinical validation. Training includes on-site, remote, and eLearning modules. Ongoing support and customer success management included.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Monarch Medical Technologies develops and sells EndoTool, an FDA-cleared Class II medical device software that delivers patient-specific insulin dosing recommendations for hospitalized patients. The platform supports both intravenous (EndoTool IV) and subcutaneous (EndoTool SubQ) insulin delivery using a proprietary adaptive algorithm, and integrates with major hospital EHR systems. A cloud-based version (EndoTool IV Cloud) received FDA 510(k) clearance in 2026.

Product overview

Monarch Medical Technologies, a Glooko company, offers the EndoTool® Glucose Management System - a family of FDA-cleared patient-specific insulin dosing solutions for hospital inpatient glycemic care. The portfolio consists of two core products: EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin dosing, both using a proprietary patient-specific algorithm that adapts to individual patient physiology. The company also launched EndoTool IV Cloud in 2026, a cloud-based architecture enabling more scalable deployment. All products are backed by clinical evidence and designed to reduce hypoglycemia risk while standardizing insulin dosing protocols across healthcare systems.

Differentiator

Problem solved

Functional benefit

Brands

• EndoTool: FDA-cleared patient-specific insulin dosing system for inpatient glycemic management, including EndoTool IV for intravenous insulin therapy and EndoTool SubQ for subcutaneous insulin delivery. The platform uses patented patient-specific algorithms to provide real-time insulin dosing recommendations for hospitalized patients.

Products and services

• EndoTool IV

Quantifiable outcome

• Severe hypoglycemia rate reduced to 0.005% (Sharp HealthCare)
• +5 more outcomes

Named customers10 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability2 records

Feature4 records

Partnerships

Six partnerships are on record, tiered minor and core.

• mylife Diabetes CareminorGTM or Marketing Partner · 14 May 2026Glooko announced an expanded partnership with mylife Diabetes Care, positioning Glooko as the primary data management platform for mylife's connected diabetes products.
• GlookocoreStrategic or Co-development Partner · 1 September 2025Glooko acquired Monarch Medical Technologies in September 2025 to expand its connected diabetes care platform into inpatient glycemic management. The acquisition integrates EndoTool with Glooko's outpatient diabetes management solutions to create a comprehensive hospital-to-home diabetes management platform. Following the $100M Series F financing in October 2024, Glooko positioned EndoTool as a core component of its integrated diabetes ecosystem.
• EpiccoreTechnology or IntegrationEndoTool integrates with Epic EHR systems, enabling clinicians to launch EndoTool and receive dosing recommendations directly within the Epic workflow.
• Cerner (Oracle Health)coreTechnology or IntegrationEndoTool integrates with Cerner (now Oracle Health) EHR systems, allowing seamless data exchange and workflow optimization.
• MeditechcoreTechnology or IntegrationEndoTool integrates with Meditech EHR platforms for hospitals using Meditech's electronic medical record systems.
• Oracle HealthcoreTechnology or IntegrationFollowing Cerner's acquisition by Oracle, EndoTool supports integration with Oracle Health platforms.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Glytec: Glytec is the closest direct competitor to Monarch's EndoTool, offering the eGlycemic Management System for hospital inpatient insulin dosing. Both companies compete head-to-head in selling FDA-cleared, EHR-integrated glycemic decision support software to U.S. hospital systems and health networks.

Broad incumbents

• Roche Diabetes Care: Roche Diabetes Care is a large incumbent offering insulin pumps, CGM systems, and digital diabetes management tools. While its core focus is outpatient and home-use devices, it operates adjacent to Monarch's hospital dosing space and competes for diabetes management budget within integrated delivery networks.
• Medtronic Diabetes: Medtronic Diabetes is a leader in insulin pumps and automated insulin delivery systems aimed primarily at outpatient diabetes management. It is comparable to Monarch as part of the broader diabetes technology ecosystem targeting the same endocrinologist and health system stakeholders.
• Dexcom: Dexcom is a leading continuous glucose monitor (CGM) manufacturer whose devices increasingly feed real-time glucose data into inpatient dosing workflows. Its data is complementary to but increasingly overlapping with Monarch's dosing decisions, making it a relevant ecosystem peer.
• Abbott Diabetes Care: Abbott Diabetes Care manufactures FreeStyle Libre CGM systems used in hospital settings alongside inpatient insulin protocols. It competes for the same hospital glucose management budget and increasingly integrates its CGM data into dosing and analytics workflows comparable to Monarch's.
• Insulet Corporation: Insulet manufactures the Omnipod tubeless insulin pump, primarily for outpatient diabetes management. It is a broad diabetes technology incumbent whose automated insulin delivery offerings compete for the broader hospital and health system diabetes management wallet.
• Tandem Diabetes Care: Tandem Diabetes Care produces insulin pumps and automated insulin delivery systems including the t:slim X2 with Control-IQ. It targets the same endocrinologist decision-makers and increasingly the inpatient dosing workflow as Monarch's EndoTool.

Others

• Novo Nordisk: Novo Nordisk is a leading insulin and GLP-1 manufacturer that supplies the drugs whose dosing Monarch's software optimizes. It is a thematically related player rather than a direct competitor but influences hospital insulin protocols and partnerships.
• Eli Lilly: Eli Lilly manufactures insulins and GLP-1 therapies whose dosing and titration Monarch's software manages. As a major diabetes pharmaceutical incumbent, it shapes hospital protocols and is a natural adjacent ecosystem participant rather than direct competitor.
• Glooko: Glooko is the parent company of Monarch following the September 2025 acquisition and operates the outpatient diabetes management and remote patient monitoring platform that Monarch's EndoTool is now integrated with. It is the platform partner and customer-facing commercial vehicle for Monarch's hospital-to-home expansion.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/monarchmedtech
• LinkedInlinkedin.com/company/monarch-medical-technologies

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Monarch Medical Technologies